NO20041225L - Rekombinant anti-osteopontinantistoff og anvendelse derav - Google Patents

Rekombinant anti-osteopontinantistoff og anvendelse derav

Info

Publication number
NO20041225L
NO20041225L NO20041225A NO20041225A NO20041225L NO 20041225 L NO20041225 L NO 20041225L NO 20041225 A NO20041225 A NO 20041225A NO 20041225 A NO20041225 A NO 20041225A NO 20041225 L NO20041225 L NO 20041225L
Authority
NO
Norway
Prior art keywords
recombinant anti
osteopontin antibody
osteopontin
antibody
recombinant
Prior art date
Application number
NO20041225A
Other languages
English (en)
Norwegian (no)
Inventor
Toshimitsu Uede
Shigeyuki Kon
Nobuchika Yamamoto
Hirofumi Higuchi
Masaharu Torikai
Yoshiyuki Tokieda
Toshihiro Nakashima
Hiroaki Maeda
Original Assignee
Immuno Biological Lab Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Biological Lab Co Ltd filed Critical Immuno Biological Lab Co Ltd
Publication of NO20041225L publication Critical patent/NO20041225L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20041225A 2001-09-25 2004-03-23 Rekombinant anti-osteopontinantistoff og anvendelse derav NO20041225L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001290700 2001-09-25
PCT/JP2002/009868 WO2003027151A1 (fr) 2001-09-25 2002-09-25 Anticorps recombinant anti-osteopontine et son utilisation

Publications (1)

Publication Number Publication Date
NO20041225L true NO20041225L (no) 2004-05-25

Family

ID=19112969

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041225A NO20041225L (no) 2001-09-25 2004-03-23 Rekombinant anti-osteopontinantistoff og anvendelse derav

Country Status (16)

Country Link
US (1) US7241873B2 (hu)
EP (1) EP1431310A4 (hu)
JP (1) JPWO2003027151A1 (hu)
KR (1) KR20040048899A (hu)
CN (1) CN100352844C (hu)
AU (1) AU2002332290B2 (hu)
BR (1) BR0213078A (hu)
CA (1) CA2461529A1 (hu)
HK (1) HK1084127A1 (hu)
HU (1) HUP0402049A3 (hu)
MX (1) MXPA04002837A (hu)
NO (1) NO20041225L (hu)
NZ (1) NZ531818A (hu)
PL (1) PL369446A1 (hu)
RU (1) RU2305111C2 (hu)
WO (1) WO2003027151A1 (hu)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234524A1 (en) * 2001-04-05 2004-11-25 Toshimitsu Uede Anti-osteopontin antibody and use thereof
JPWO2003027151A1 (ja) 2001-09-25 2005-01-06 株式会社 免疫生物研究所 組換え抗オステオポンチン抗体およびその用途
US7678889B2 (en) * 2002-08-06 2010-03-16 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
US20070274993A1 (en) * 2003-05-23 2007-11-29 Immuno-Biological Laboratories Co., Ltd. Immunocompetent Cell Activation Inhibitor and Use Thereof
EP2369348A1 (en) * 2003-11-07 2011-09-28 Ciphergen Biosystems, Inc. Biomarkers for Alzheimer's disease
JP4495208B2 (ja) * 2004-02-27 2010-06-30 エフ．ホフマン−ラ ロシュ アーゲー 抗ｃｃｐおよび血清アミロイドａの測定による慢性関節リウマチの評価方法
EP1721163B1 (en) * 2004-02-27 2015-04-29 Roche Diagnostics GmbH Method of assessing rheumatoid arthritis by measuring rheumatoid factor and interleukin-6
EP1841455A1 (en) * 2005-01-24 2007-10-10 Amgen Inc. Humanized anti-amyloid antibody
US8071367B2 (en) * 2005-05-04 2011-12-06 Commonwealth Scientific And Industrial Research Organisation Selecting, culturing and creating lineage committed hematopoietic stem cells
MY185597A (en) * 2005-09-20 2021-05-24 Avantor Performance Mat Inc Vegetarian protein a preparation and methods thereof
ATE553130T1 (de) * 2006-05-31 2012-04-15 Astellas Pharma Inc Humanisierter anti-human-osteopontin-antikörper
AU2007309979B2 (en) * 2006-10-26 2012-06-28 Gene Techno Science Co., Ltd. Antibody against RGD in amino acid sequence of extracellular matrix protein and production method and use of the same
KR101436578B1 (ko) * 2007-03-30 2014-09-01 슈 생-쥐스땡 척추 측만증의 발병 위험성을 측정하는 방법, 척추 측만증에 걸린 대상자를 계층화하는 방법, 척추 측만증에 걸린 대상자에 있어서 고정기의 효능을 평가하는 방법, 및 이를 위한 키트
KR100894265B1 (ko) * 2007-06-05 2009-04-21 재단법인서울대학교산학협력재단 골형성 촉진 펩타이드를 함유하는 주입형 골재생재
US9040666B2 (en) 2007-07-13 2015-05-26 Bac Ip B.V. Single-domain antigen-binding proteins that bind mammalian IgG
JP5679818B2 (ja) * 2007-12-13 2015-03-04 モンサント テクノロジー エルエルシー 早期妊娠診断のための組成物および方法
CA2709354C (en) 2007-12-21 2014-06-17 Amgen Inc. Anti-amyloid antibodies and uses thereof
RU2503720C2 (ru) 2008-01-11 2014-01-10 Астеллас Фарма Инк. УЛУЧШЕННОЕ ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К ЧЕЛОВЕЧЕСКОМУ α9-ИНТЕГРИНУ
US8614296B2 (en) * 2008-04-24 2013-12-24 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof
US9029508B2 (en) * 2008-04-29 2015-05-12 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
EP3002299A1 (en) * 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
CN102112494A (zh) * 2008-06-03 2011-06-29 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
JP5674654B2 (ja) * 2008-07-08 2015-02-25 アッヴィ・インコーポレイテッド プロスタグランジンｅ２二重可変ドメイン免疫グロブリンおよびその使用
CA2753280C (en) 2009-02-23 2017-04-25 Gene Techno Science Co., Ltd. Anti-human .alpha.9 integrin antibody and use thereof
AU2010242840B2 (en) * 2009-05-01 2014-04-17 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2480665A4 (en) * 2009-09-24 2013-04-03 Gene Techno Science Co Ltd HUMANIZED ANTIBODIES TO THE AMINO ACID SEQUENCE RGD OF EXTRACELLULAR MATRIX PROTEIN AND ITS USE
KR20140015139A (ko) * 2009-10-15 2014-02-06 애브비 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CN103298834A (zh) 2010-08-03 2013-09-11 Abbvie公司 双重可变结构域免疫球蛋白及其用途
BR112013004581A2 (pt) 2010-08-26 2017-06-27 Abbvie Inc imunoglobulinas de domínio variável dual e seus usos
US20120263722A1 (en) * 2010-11-04 2012-10-18 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
JP2014523867A (ja) 2011-05-27 2014-09-18 カロバイオス ファーマシューティカルズ インコーポレイティッド 抗ｅｍｒ１抗体
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
PE20151179A1 (es) 2012-11-01 2015-09-12 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
BR112015023797A2 (pt) 2013-03-15 2017-10-24 Abbvie Inc proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
UA121866C2 (uk) * 2014-08-06 2020-08-10 Астеллас Фарма Інк. АНТИТІЛО ДО Ig<font face="Symbol">b </font>ЛЮДИНИ
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US10349259B2 (en) * 2016-09-23 2019-07-09 Apple Inc. Broadcasting a device state in a wireless communication network
JP2022543657A (ja) * 2019-08-09 2022-10-13 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー オステオポンチンに対する治療用抗体
CN115558015B (zh) * 2022-10-12 2024-01-19 生工生物工程（上海）股份有限公司 一种从gst融合蛋白酶切后的产物中纯化无gst标签的目的蛋白的方法和产品

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US171358A (en) * 1875-12-21 Improvement in machines for trimming and punching roofing-slates
US125023A (en) * 1872-03-26 Improvement in sand dredging-machines
US239400A (en) * 1881-03-29 Tobacco-fork
US1408113A (en) * 1921-01-28 1922-02-28 Mason Richard Colbert Well-measuring device
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2213148T3 (es) 1993-03-11 2004-08-16 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anticuerpo monoclonal dirigido contra el vih.
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
EP0705842A2 (en) 1994-10-06 1996-04-10 Hoechst Aktiengesellschaft Regulated genes by stimulation of chondrocytes with 1L-1beta
US6686444B2 (en) 1996-08-22 2004-02-03 Children's Medical Center Corporation Osteopontin derived chemotactic peptides and methods of use
WO1998008379A1 (en) 1996-08-27 1998-03-05 Dana-Farber Cancer Institute Methods for identifying modulators of cellular interactions mediated by osteopontin
WO1998056405A1 (en) 1997-06-10 1998-12-17 Whitehead Institute For Biomedical Research A method of modulating immune response with osteopontin
CA2300194A1 (en) 1997-08-15 1999-02-25 Children's Medical Center Corporation Osteopontin coated surfaces and methods of use
US6118044A (en) * 1997-11-14 2000-09-12 Sankyo Company, Limited Transgenic animal allergy models and methods for their use
US6414219B1 (en) 1998-06-30 2002-07-02 Rutgers, The State University Of New Jersey Osteopontin knock-out mouse and methods of use thereof
AU777432B2 (en) * 1999-04-15 2004-10-14 Children's Medical Center Corporation Osteopontin-derived chemotactic and inhibitory agents and uses therefor
MXPA01010332A (es) 1999-04-15 2002-09-18 Childrens Medical Center Metodos y composiciones para modular una respuesta inmunitaria.
US7504232B2 (en) 2000-03-23 2009-03-17 Smithkline Beecham Corporation Method of screening for inhibitors of osteopontin
US20060105013A1 (en) 2000-10-18 2006-05-18 Samy Ashkar Osteopontin-coated surfaces and methods of use
US20040234524A1 (en) * 2001-04-05 2004-11-25 Toshimitsu Uede Anti-osteopontin antibody and use thereof
KR100932465B1 (ko) 2001-07-19 2009-12-17 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 인간형 항인간 ＩｇＥ 수용체 항체 및 항체 단편
JPWO2003027151A1 (ja) 2001-09-25 2005-01-06 株式会社 免疫生物研究所 組換え抗オステオポンチン抗体およびその用途
US7282490B2 (en) 2001-11-21 2007-10-16 The Board Of Trustees Of The Leland Stanford Junior University Osteopontin-related compositions and methods
CN103518888A (zh) * 2013-10-14 2014-01-22 李民庆 一种养心宁神茶配方

Also Published As

Publication number Publication date
CN100352844C (zh) 2007-12-05
CN1688604A (zh) 2005-10-26
MXPA04002837A (es) 2005-11-04
WO2003027151A1 (fr) 2003-04-03
HUP0402049A2 (hu) 2005-01-28
BR0213078A (pt) 2004-11-23
AU2002332290B2 (en) 2007-11-08
RU2004112540A (ru) 2005-04-20
NZ531818A (en) 2005-10-28
KR20040048899A (ko) 2004-06-10
CA2461529A1 (en) 2003-04-03
US20060002923A1 (en) 2006-01-05
EP1431310A1 (en) 2004-06-23
HUP0402049A3 (en) 2009-04-28
US7241873B2 (en) 2007-07-10
EP1431310A4 (en) 2005-03-23
PL369446A1 (en) 2005-04-18
JPWO2003027151A1 (ja) 2005-01-06
RU2305111C2 (ru) 2007-08-27
HK1084127A1 (en) 2006-07-21

Similar Documents

Publication Publication Date Title
NO20041225L (no) Rekombinant anti-osteopontinantistoff og anvendelse derav
DK1390389T3 (da) Cripto-blokerende antistoffer og anvendelser deraf
NO20034405D0 (no) Anti-ostepontin-antistoff og anvendelse derav
AU2002332290A1 (en) Recombinant anti-osteopontin antibody and use thereof
HUP0400284A3 (en) Recombinant tumor specific antibody and use thereof
DK1163271T3 (da) Rekombinant IL-18 antistoffer og deres anvendelse
NO20034396L (no) Rekombinante antistoff uttrykt sammen med GnTIII
NO20033418D0 (no) Immunregulatoriske antistoffer og anvendelse derav
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
DK1711207T3 (da) Interferon-alpha-antistoffer og anvendelse heraf
DK1746375T3 (da) Oxygendrevet forbrændingssystem og anvendelser deraf
NO20033387D0 (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
NO20033456L (no) Modifiserte og stabiliserte GDF-propeptider og anvendelse derav
DE60124863D1 (de) Gegen menschliche interleukin-1-beta gerichtete rekombinante antikörper
DK2662390T3 (da) Interferon alpha receptor 1-antistoffer og anvendelse heraf
DE60222658D1 (de) Monoklonaler anti-cd-40-antikörper
DK1411064T3 (da) Gangliosid-associerede rekombinante antistoffer og anvendelsen deraf i diagnosen og behandlingen af tumorer
NO20034159L (no) Östrogen-gestagen-kombinasjonspreparat og anvendelse derav
DE50206094D1 (de) Substituierte isoindole und ihre verwendung
DE50202730D1 (de) Substituierte isoindole und ihre verwendung
EP1589033A4 (en) ANTIBODY AND ITS USE
DE60205008D1 (de) Kettelverfahren und -vorrichtung
DE60219418T8 (de) Silanylphenole und -naphthole
EP1437367A4 (en) ANTIBODIES AND ITS USE
EP1627888A4 (en) ANTIBODY AND ITS USE

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN 6 VINGTOFT POSTBOKS 1003 SENTRUM OSLO, 0

FC2A Withdrawal, rejection or dismissal of laid open patent application